Pete Anevski, Progyny CEO

Fer­til­i­ty ben­e­fits com­pa­ny Prog­y­ny shares how it han­dles start­up val­u­a­tions when look­ing for deals

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)

When Prog­y­ny went pub­lic in 2019, it was one of a hand­ful of health­care star­tups brav­ing a large­ly untest­ed mar­ket.

Four years lat­er, Prog­y­ny is trad­ing in line with where it start­ed the year and up 93% from its de­but. Prog­y­ny is a fer­til­i­ty ben­e­fits com­pa­ny that works with self-in­sured em­ploy­ers. It’s a ben­e­fit in­creas­ing­ly be­ing of­fered by em­ploy­ers, and for the full year of 2022 it was a $787 mil­lion busi­ness for Prog­y­ny. The com­pa­ny works with 390 em­ploy­er clients as of 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.